GTBP
HEALTHCAREGT Biopharma Inc
$0.40+0.02 (+5.95%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GTBP Today?
No stock-specific AI insight has been generated for GTBP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.26$3.85
$0.40
Fundamentals
Market Cap$14M
P/E Ratio—
EPS$-6.53
Dividend Yield—
Dividend / Share—
ROE-13.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding35.6M
GTBP News
20 articles- Replays from RedChip's Biotech Investor Conference Now AvailableYahoo Finance·Apr 20, 2026
- RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech InnovationYahoo Finance·Apr 10, 2026
- GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Mar 16, 2026
- GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Yahoo Finance·Mar 12, 2026
- GT Biopharma to Participate in the 38th Annual Roth ConferenceYahoo Finance·Mar 11, 2026
- GT Biopharma Reports Full Year 2025 Financial ResultsYahoo Finance·Mar 2, 2026
- GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth ConferenceYahoo Finance·Feb 17, 2026
- GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3Yahoo Finance·Feb 3, 2026
- GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancersYahoo Finance·Jan 15, 2026
- Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatmentThe Street·Dec 8, 2025
- GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 TrialsYahoo Finance·Nov 19, 2025
- GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 14, 2025
- GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic MalignanciesYahoo Finance·Oct 23, 2025
- EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood CancersYahoo Finance·Oct 8, 2025
- GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas SummitYahoo Finance·Oct 6, 2025
- GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 4, 2025
- GT Biopharma Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 14, 2025
- GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2Yahoo Finance·Aug 11, 2025
- GT Biopharma Appoints New Member to its Board of DirectorsYahoo Finance·Jun 13, 2025
- GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation SignalsYahoo Finance·May 19, 2025
All 20 articles loaded
Price Data
Open$0.37
Previous Close$0.38
Day High$0.42
Day Low$0.37
52 Week High$3.85
52 Week Low$0.26
52-Week Range
$0.26$3.85
$0.40
Fundamentals
Market Cap$14M
P/E Ratio—
EPS$-6.53
Dividend Yield—
Dividend / Share—
ROE-13.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding35.6M
About GT Biopharma Inc
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—